Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Renal cell carcinoma.

W Kimryn Rathmell1, Caroline A Martz, Brian I Rini

  • 1University of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina 27599-7295, USA. rathmell@med.unc.edu

Current Opinion in Oncology
|April 7, 2007
PubMed
Summary

Recent advances in renal cell carcinoma (RCC) treatment include new targeted therapies and antiangiogenic agents. These innovations improve survival outcomes for metastatic disease and drive further research into RCC

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Casdatifan shows durable response linked to HIF-2α biology in kidney cancer.

Nature·2026
Same author

Podcast on the Emerging Role of PD-(L)1/VEGF Bispecific Antibodies in the Evolving Advanced Renal Cell Carcinoma Treatment Landscape.

Oncology and therapy·2026
Same author

Comprehensive Genomic and Transcriptomic Characterization of Matched Primary and Recurrent Tumors in High-risk Localized Renal Cell Carcinoma.

European urology·2026
Same author

Cardiac biomarkers in patients with renal cell carcinoma treated with immune checkpoint inhibitors.

The oncologist·2026
Same author

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of renal cell carcinoma, version 3.0.

Journal for immunotherapy of cancer·2026
Same author

Reconsidering adjuvant and perioperative immune-checkpoint inhibition: de-escalation, expansion and personalization.

Nature reviews. Clinical oncology·2026

Area of Science:

  • Oncology
  • Translational Research

Background:

  • Renal cell carcinoma (RCC) is a complex malignancy with evolving treatment paradigms.
  • Understanding the molecular underpinnings of RCC is crucial for developing effective therapies.

Purpose of the Study:

  • To review recent advancements in the biology and treatment of renal cell carcinoma.
  • To highlight the expanded use of antiangiogenic agents and other novel drug mechanisms.
  • To report on emerging biomarkers for prognostic indicators in RCC.

Main Methods:

  • Literature review of recent contributions to renal cell carcinoma research.
  • Analysis of emerging targeted therapeutics and their impact on metastatic disease.
  • Investigation of novel drug mechanisms and prognostic biomarkers.

Related Experiment Videos

Main Results:

  • Significant progress in understanding RCC molecular biology.
  • Introduction of new targeted therapeutics benefiting patients with metastatic RCC.
  • Identification of promising biomarkers for survival and treatment response prediction.

Conclusions:

  • The management of metastatic renal cell carcinoma has been revolutionized by recent drug approvals.
  • New treatments demonstrate improved progression-free and overall survival.
  • These advancements stimulate further translational studies in RCC.